Research
Hormonal
GLP-1 receptor (GLP-1R) agonists significantly reduce the occurrence of major adverse cardiovascular events in individuals with type 2 diabetes (T2D).
Practitioners should consider GLP-1R agonists as a therapeutic option for reducing cardiovascular risks in T2D patients.
StrongSupportsmedium confidence
Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D.
Why this rating
Based on data from several cardiovascular outcome trials.
Source
Incretin-mediated control of cardiac energy metabolism
Jordan S. F. Chan et al. · Journal of Endocrinology · 2024
DOI 10.1530/joe-24-0011
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →